Cargando…

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series

Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Šimičević, Livija, Slišković, Ana Marija, Kirhmajer, Majda Vrkić, Ganoci, Lana, Holik, Hrvoje, Palić, Jozefina, Samardžić, Jure, Božina, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966833/ https://www.ncbi.nlm.nih.gov/pubmed/36827667 http://dx.doi.org/10.3390/pharmacy11010029

Ejemplares similares

Use of pharmacogenomics in elderly patients treated for cardiovascular diseases
por: Božina, Nada, et al.
Publicado: (2020)

UGT2B7 c.-161C>T Polymorphism Frequency in Croatian Population
por: Božina, Tamara, et al.
Publicado: (2023)

Drug-drug-gene Interactions as Mediators of Adverse Drug Reactions to Diclofenac and Statins: A Case Report and Literature Review
por: Božina, Nada, et al.
Publicado: (2021)

Vascular Ehlers-Danlos syndrome, an often unrecognized clinical entity: a case report of a novel mutation in the COL3A1 gene
por: Huljev Frković, Sanda, et al.
Publicado: (2022)

Atrial fibrillation as a contributing factor in the diagnostic algorithm for coronary subclavian steal syndrome and cardiac tamponade following coronary artery bypass graft surgery: a case study
por: Perčin, Luka, et al.
Publicado: (2021)

Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis
por: Mardi, Parham, et al.
Publicado: (2023)

Preliminary study on changes in BDNF in patients with depression after percutaneous coronary intervention
por: Medved, S., et al.
Publicado: (2023)

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
por: Radosavljevic, Milica, et al.
Publicado: (2023)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients
por: Hou, Huimin, et al.
Publicado: (2020)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Rivaroxaban: Bleeding from fungating breast cancer wound: case report
Publicado: (2021)

Rivaroxaban: A Possible Cause of Guillain–Barre Syndrome
por: Karri, Madhavi, et al.
Publicado: (2019)

Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report
por: Börekci, Elif
Publicado: (2019)

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
por: Kline, Jeffrey A., et al.
Publicado: (2016)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2020)

Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile
por: Di Maso, Vittorio, et al.
Publicado: (2014)

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
por: Piatkov, Irina, et al.
Publicado: (2012)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
por: Kim, Hamin, et al.
Publicado: (2023)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
por: Gruenebaum, Dane D., et al.
Publicado: (2014)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
por: Sennesael, Anne-Laure, et al.
Publicado: (2018)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
por: Chen, Xiehui, et al.
Publicado: (2021)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Possible pharmacogenetic factors in clozapine treatment failure: a case report
por: Whiskey, Eromona, et al.
Publicado: (2021)

Adiponectin is Not Associated With Blood Pressure in Normotensives and Untreated Hypertensives With Normal Kidney Function
por: Ivković, Vanja, et al.
Publicado: (2014)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
por: Holik, Hrvoje, et al.
Publicado: (2023)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy
por: Corallo, Carmela E., et al.
Publicado: (2015)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure
por: Sopek Merkaš, Ivana, et al.
Publicado: (2021)

A Case Report of Rivaroxaban-Induced Urticaria and Angioedema With Possible Cross-Reaction to Dabigatran
por: Patil, Tanvi, et al.
Publicado: (2019)

Antithrombotics in heart failure
por: Miličić, Davor, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_asvfucctcpde8vrst54364d88n